SG Americas Securities LLC Has $183,000 Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

SG Americas Securities LLC reduced its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 23.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,508 shares of the company’s stock after selling 6,786 shares during the period. SG Americas Securities LLC’s holdings in Health Catalyst were worth $183,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its position in Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the period. Quarry LP grew its stake in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares in the last quarter. Perfromance Wealth Partners LLC bought a new position in Health Catalyst during the second quarter worth about $64,000. Mackenzie Financial Corp acquired a new stake in Health Catalyst in the 2nd quarter worth about $70,000. Finally, EntryPoint Capital LLC bought a new stake in Health Catalyst in the 1st quarter valued at about $98,000. 85.00% of the stock is currently owned by institutional investors.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the sale, the chief operating officer now owns 150,006 shares of the company’s stock, valued at $928,537.14. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the transaction, the chief operating officer now owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,396 shares of company stock worth $258,415. Corporate insiders own 2.70% of the company’s stock.

Health Catalyst Stock Down 6.4 %

NASDAQ:HCAT opened at $8.08 on Thursday. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The stock’s 50-day simple moving average is $7.84 and its 200 day simple moving average is $6.98. The firm has a market capitalization of $477.00 million, a PE ratio of -4.37 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) earnings per share. On average, analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Stephens reduced their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Piper Sandler dropped their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus price target of $11.58.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.